Moderna (MRNA) Tops Q2 EPS by 32c

Moderna (NASDAQ: MRNA) reported Q2 EPS of ($3.62), $0.32 better than the analyst estimate of ($3.94). Revenue for the quarter came in at $344 million versus the consensus estimate of $307.65 million.

Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination rates.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
• Lennar Corp. (LEN) Misses Q2 EPS by 1c